A novel approach for cancer immunotherapy

Tumor cells with anchored superantigen SEA generate effective antitumor immunity

Wenxue Ma, Hai Yu, Qingqing Wang, Hongchuan Jin, Joyce C Solheim, Vinod Labhasetwar

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Murine B16 melanoma cell line is poorly immunogenic and highly aggressive. We recently reported that the transmembrane staphylococcal enterotoxin A (TM-SEA) anchors onto B16 cells and stimulates lymphocyte proliferation. The purpose of the study was to investigate whether vaccination with B16 cells bearing membrane-anchored TM-SEA fusion protein could cause tumor-specific immunity. Mice in the therapeutic vaccination group received B16 tumor inoculations, followed by treatment with B16-TM-SEA vaccine or control vaccines. Mice in the prophylactic vaccination group were given B16-TM-SEA vaccine or control vaccines, followed by challenge with wild type B16 or control EL4 cells. Significant tumor growth inhibition, prolongation of survival, and marked augmentation of NK and CTL activities were observed in mice which received B16-TM-SEA vaccine as compared to controls. Overall, our results suggest that the TM-SEA cellular vaccine is a novel and effective strategy for cancer immunotherapy.

Original languageEnglish (US)
Pages (from-to)294-301
Number of pages8
JournalJournal of Clinical Immunology
Volume24
Issue number3
DOIs
StatePublished - May 1 2004

Fingerprint

Superantigens
Immunotherapy
Immunity
Vaccines
Neoplasms
Vaccination
Experimental Melanomas
Staphylococcal enterotoxin A
Cell Membrane
Lymphocytes
Cell Line
Therapeutics
Growth
Proteins

Keywords

  • Immune response
  • Melanoma
  • Superantigen
  • Transmembrane
  • Vaccine

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

A novel approach for cancer immunotherapy : Tumor cells with anchored superantigen SEA generate effective antitumor immunity. / Ma, Wenxue; Yu, Hai; Wang, Qingqing; Jin, Hongchuan; Solheim, Joyce C; Labhasetwar, Vinod.

In: Journal of Clinical Immunology, Vol. 24, No. 3, 01.05.2004, p. 294-301.

Research output: Contribution to journalArticle

Ma, Wenxue ; Yu, Hai ; Wang, Qingqing ; Jin, Hongchuan ; Solheim, Joyce C ; Labhasetwar, Vinod. / A novel approach for cancer immunotherapy : Tumor cells with anchored superantigen SEA generate effective antitumor immunity. In: Journal of Clinical Immunology. 2004 ; Vol. 24, No. 3. pp. 294-301.
@article{bdc7bed33344427687a35392f652d5c8,
title = "A novel approach for cancer immunotherapy: Tumor cells with anchored superantigen SEA generate effective antitumor immunity",
abstract = "Murine B16 melanoma cell line is poorly immunogenic and highly aggressive. We recently reported that the transmembrane staphylococcal enterotoxin A (TM-SEA) anchors onto B16 cells and stimulates lymphocyte proliferation. The purpose of the study was to investigate whether vaccination with B16 cells bearing membrane-anchored TM-SEA fusion protein could cause tumor-specific immunity. Mice in the therapeutic vaccination group received B16 tumor inoculations, followed by treatment with B16-TM-SEA vaccine or control vaccines. Mice in the prophylactic vaccination group were given B16-TM-SEA vaccine or control vaccines, followed by challenge with wild type B16 or control EL4 cells. Significant tumor growth inhibition, prolongation of survival, and marked augmentation of NK and CTL activities were observed in mice which received B16-TM-SEA vaccine as compared to controls. Overall, our results suggest that the TM-SEA cellular vaccine is a novel and effective strategy for cancer immunotherapy.",
keywords = "Immune response, Melanoma, Superantigen, Transmembrane, Vaccine",
author = "Wenxue Ma and Hai Yu and Qingqing Wang and Hongchuan Jin and Solheim, {Joyce C} and Vinod Labhasetwar",
year = "2004",
month = "5",
day = "1",
doi = "10.1023/B:JOCI.0000025451.41948.94",
language = "English (US)",
volume = "24",
pages = "294--301",
journal = "Journal of Clinical Immunology",
issn = "0271-9142",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - A novel approach for cancer immunotherapy

T2 - Tumor cells with anchored superantigen SEA generate effective antitumor immunity

AU - Ma, Wenxue

AU - Yu, Hai

AU - Wang, Qingqing

AU - Jin, Hongchuan

AU - Solheim, Joyce C

AU - Labhasetwar, Vinod

PY - 2004/5/1

Y1 - 2004/5/1

N2 - Murine B16 melanoma cell line is poorly immunogenic and highly aggressive. We recently reported that the transmembrane staphylococcal enterotoxin A (TM-SEA) anchors onto B16 cells and stimulates lymphocyte proliferation. The purpose of the study was to investigate whether vaccination with B16 cells bearing membrane-anchored TM-SEA fusion protein could cause tumor-specific immunity. Mice in the therapeutic vaccination group received B16 tumor inoculations, followed by treatment with B16-TM-SEA vaccine or control vaccines. Mice in the prophylactic vaccination group were given B16-TM-SEA vaccine or control vaccines, followed by challenge with wild type B16 or control EL4 cells. Significant tumor growth inhibition, prolongation of survival, and marked augmentation of NK and CTL activities were observed in mice which received B16-TM-SEA vaccine as compared to controls. Overall, our results suggest that the TM-SEA cellular vaccine is a novel and effective strategy for cancer immunotherapy.

AB - Murine B16 melanoma cell line is poorly immunogenic and highly aggressive. We recently reported that the transmembrane staphylococcal enterotoxin A (TM-SEA) anchors onto B16 cells and stimulates lymphocyte proliferation. The purpose of the study was to investigate whether vaccination with B16 cells bearing membrane-anchored TM-SEA fusion protein could cause tumor-specific immunity. Mice in the therapeutic vaccination group received B16 tumor inoculations, followed by treatment with B16-TM-SEA vaccine or control vaccines. Mice in the prophylactic vaccination group were given B16-TM-SEA vaccine or control vaccines, followed by challenge with wild type B16 or control EL4 cells. Significant tumor growth inhibition, prolongation of survival, and marked augmentation of NK and CTL activities were observed in mice which received B16-TM-SEA vaccine as compared to controls. Overall, our results suggest that the TM-SEA cellular vaccine is a novel and effective strategy for cancer immunotherapy.

KW - Immune response

KW - Melanoma

KW - Superantigen

KW - Transmembrane

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=3543126002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543126002&partnerID=8YFLogxK

U2 - 10.1023/B:JOCI.0000025451.41948.94

DO - 10.1023/B:JOCI.0000025451.41948.94

M3 - Article

VL - 24

SP - 294

EP - 301

JO - Journal of Clinical Immunology

JF - Journal of Clinical Immunology

SN - 0271-9142

IS - 3

ER -